title: Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.
abstract: Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin. As carcinomas progress, these tumors may lose epithelial morphology and acquire mesenchymal characteristics which contribute to metastatic potential. An epithelial-to-mesenchymal transition (EMT) similar to the process critical for embryonic development is thought to be an important mechanism for promoting cancer invasion and metastasis. Epithelial-to-mesenchymal transitions have been induced in vitro by transient or unregulated activation of receptor tyrosine kinase signaling pathways, oncogene signaling and disruption of homotypic cell adhesion. These cellular models attempt to mimic the complexity of human carcinomas which respond to autocrine and paracrine signals from both the tumor and its microenvironment. Activation of the epidermal growth factor receptor (EGFR) has been implicated in the neoplastic transformation of solid tumors and overexpression of EGFR has been shown to correlate with poor survival. Notably, epithelial tumor cells have been shown to be significantly more sensitive to EGFR inhibitors than tumor cells which have undergone an EMT-like transition and acquired mesenchymal characteristics, including non-small cell lung (NSCLC), head and neck (HN), bladder, colorectal, pancreas and breast carcinomas. EGFR blockade has also been shown to inhibit cellular migration, suggesting a role for EGFR inhibitors in the control of metastasis. The interaction between EGFR and the multiple signaling nodes which regulate EMT suggest that the combination of an EGFR inhibitor and other molecular targeted agents may offer a novel approach to controlling metastasis.
authors.affiliation: OSI Pharmaceuticals Inc., 1 Bioscience Park Dr., Farmingdale, NY 11735, USA. sbarr@osip.com
authors.forename: Sharon
authors.initials: S
authors.lastname: Barr
authors.forename: Stuart
authors.initials: S
authors.lastname: Thomson
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Buck
authors.forename: Suzanne
authors.initials: S
authors.lastname: Russo
authors.forename: Filippo
authors.initials: F
authors.lastname: Petti
authors.forename: Izabela
authors.initials: I
authors.lastname: Sujka-Kwok
authors.forename: Alexandra
authors.initials: A
authors.lastname: Eyzaguirre
authors.forename: Maryland
authors.initials: M
authors.lastname: Rosenfeld-Franklin
authors.forename: Neil W
authors.initials: NW
authors.lastname: Gibson
authors.forename: Mark
authors.initials: M
authors.lastname: Miglarese
authors.forename: David
authors.initials: D
authors.lastname: Epstein
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Iwata
authors.forename: John D
authors.initials: JD
authors.lastname: Haley
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology*; D004848:Epithelium / Q000473:pathology*; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D008648:Mesoderm / Q000473:pathology*; D009361:Neoplasm Invasiveness / Q000473:pathology*
chemical_list: D066246:ErbB Receptors